| Drug / Therapy | Ivonescimab |
| Indication | SMMT PDUFA |
| Decision Type | PDUFA |
| Conditions | SMMT PDUFA |
| Interventions | Ivonescimab |
Summit Therapeutics Inc. (SMMT) operates in the Biotech / Pharma sector. The current BiotechSign Score is 48 (Grade: D).
Biotech companies frequently raise capital through secondary offerings, ATM programs, and convertible notes. Before or after major FDA decisions, dilution events are common. Understanding a company's dilution history is critical for managing risk around catalyst dates.
The PDUFA date for Ivonescimab by Summit Therapeutics Inc. (SMMT) is scheduled for November 14, 2026. This is the target date for the FDA to make a decision on this application.
Ivonescimab is being developed by Summit Therapeutics Inc. for the treatment of SMMT PDUFA. It is under FDA review.
If Ivonescimab receives FDA approval, Summit Therapeutics Inc. (SMMT) would be able to market the drug in the United States for SMMT PDUFA. This typically leads to significant stock price movement for biotech companies. Investors should monitor the PDUFA date closely.
Biotech companies often raise capital through share offerings, which can dilute existing shareholders. You can check the current dilution risk for SMMT on DilutionWatch at dilutionwatch.com/stock/SMMT.html.
You can view the full BiotechSign company profile for Summit Therapeutics Inc. (SMMT) at biotechsign.com/app/company/SMMT, which includes the BiotechSign Score, signal history, clinical trial data, and insider trading activity.
This page is for informational purposes only and does not constitute investment advice. FDA decision dates are subject to change. Clinical trial outcomes are inherently uncertain. Biotech stocks are highly volatile — past performance does not guarantee future results. Always consult a qualified financial advisor before making investment decisions. BiotechSign is not a registered investment advisor.